Cure Parkinson’s and Alzheimer’s Research UK announce a partnership
Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach. We are recognising the overlap in underlying biological...
Learn more
Diabetes dual agonist drugs for Parkinson’s
Glucagon-like peptide 1 receptor (or GLP-1R) agonists are recognised as a frontline treatment for diabetes. Researchers have recently been developing the next generation of treatment for diabetes which target GLP-1R and another protein called gastric inhibitory polypeptide (or GIP) at the same time. These combination…
GCase and Parkinson’s: a new perspective
Recently researchers have provided new insights into how small defects in a region of DNA called the GBA gene could be affecting cell biology leading to Parkinson’s.
Clinical results from Enterin trial
Biotech company Enterin has announced the results of their phase 2 clinical trial of ENT-01 indicating that it had a positive benefit on the gut symptoms associated with Parkinson’s.
The mannitol pilot study results
The findings of a randomised, blinded clinical trial of the sweetener mannitol have been published. The results indicate that the molecule is safe and tolerable, but the study has not replicated the benefits that had previously been reported.
Exercise and Parkinson’s
It is a well-known fact that exercise is important for our general wellbeing. Recently, there has been a lot of new research published indicating that exercise could also potentially improve the lives of people with Parkinson’s. In late 2019, the results of a clinical trial…